Roundtable: Perspectives on the FDA Guidance for Clinical Decision Software
Clinical decision support (CDS) software is a challenging regulatory space. Should it be regulated as a device? And if it is a device, what does that mean for the software development and testing?
FDA recently published final guidance on the topic, and while the document provides some helpful clarifications, there are still areas that remain a little perplexing.
Conquer the confusion with this webinar, presented by device regulatory experts Alethea Wieland, President & COO of Clinical Research Strategies and Managing Expert at Advarra Consulting, and Advarra IRB Chairpersons Robert Romanchuk and Erin Odor. In addition to providing an overview of the final guidance, they will also conduct a roundtable discussion of case studies to help attendees better understand how the guidance and other device regulations might and might not apply.
Learning Objectives:
- Describe the criteria for assessing whether CDS software is regulated as a medical device
- Explain the impact of certain regulatory designations on CDS software development and marketing
- Assess CDS software projects to determine the appropriate regulatory pathway
Presented By
Alethea Wieland
President and CEO, Clinical Research Strategies
Advarra
Robert Romanchuk
IRB Chairperson
Advarra
Erin Odor
MA, CIP
IRB Chairperson
Advarra
n/a
n/a
n/a
n/a
DATE: June 17, 2021
Time: 1 pm ET | 10 am PT
Duration: 1 hour